New Discovery unites Australia, Germany and UK Against Blood Cancers

01/02/2016 - 2 minutes

Cancer Research UK has teamed up with MSD (Merck) and the Wellcome Trust to co-develop some Inhibitors for both Cancerous and Non-cancerous blood disorders from the Australian Academia-Biotech Network.

msd_cancer_wellcome_merck_monashThe Australian Co-operative Research Centre (CRC) for Cancer Therapeutics (CTx) in Melbourne has a range of investigational inhibitors for blood disorders – including Leukemia.

CTx is collaborative partnership of leading Research Institutes, Universities and biotechs that translates Australia’s innovative research discoveries into new cancer drugs ready for clinical development.

And these inhibitors have now caught the attention of some of the European leaders in Cancer Research, including the Wellcome Trust Seeding Drug Discovery Program (UK) and the Biopharma Giant, MSD (Germany).


Cancer Research Technology (CRT) is a wholly owned subsidiary of Cancer Research UK. CRT has now ‘brokered’ the licensing rights for the Aussie inhibitor program to Germany’s MSD, for which CRT will receive $15M (€13.8M), in addition to potential milestone-regulated payments of up to €460M.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: